Market Spotlight: Thyroid Cancer
Market Spotlight: Thyroid Cancer
This Market Spotlight report covers the Thyroid cancer market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
This Market Spotlight report covers the thyroid cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence and five-year prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
- Datamonitor Healthcare estimates that in 2017, there were 559,800 incident cases of thyroid cancer worldwide, and expects that number to increase to 612,600 incident cases by 2026.
- In the same year, there were an estimated 2.0 million five-year prevalent cases of thyroid cancer worldwide, which is expected to increase to 2.2 million by 2026.
- The approved drugs in the thyroid cancer space focus on a wide variety of targets. These drugs are commonly administered via the oral route, with one product being available in an intramuscular formulation.
- The majority of industry-sponsored drugs in active clinical development for thyroid cancer are in Phase II, with two drugs in Phase I.
- Therapies in early-to-mid-stage development for thyroid cancer focus on targets such as RET, microtubules (tubulin), carcinoembryonic antigen, immune system, tumor necrosis factor-alpha, and ErbB3/HER3. These therapies are administered via the oral, intravenous, and subcutaneous routes.
- The only high-impact upcoming event in the thyroid cancer space is topline Phase II trial results for GI-6207. The overall likelihood of approval of a Phase I solid tumors asset is 5.7%, and the average probability a drug advances from Phase III is 39.4%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.2 years in the overall oncology space.
- There have been 13 licensing and asset acquisition deals involving thyroid cancer drugs during 2013–18. The $1,119m exclusive licensing agreement signed in February 2016 between Exelixis and Ipsen, for the commercialization and further development of Cometriq, was the largest deal.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for thyroid cancer have been in the early and mid-phases of development, with 91% of trials in Phase I–II, and only 9% in Phase III–IV.
- The US has a substantial lead in the number of thyroid cancer clinical trials globally. France leads the major EU markets, while China has the top spot in Asia.
- Clinical trial activity in the thyroid cancer space is dominated by completed trials. Pfizer has the highest number of completed clinical trials for thyroid cancer, with 27 trials.
- Novartis leads industry sponsors with the highest number of clinical trials for thyroid cancer, followed by Pfizer.
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
10 Radioactive iodine (RAI) therapy
10 Thyroid hormone therapy
10 External beam radiation therapy
11 Targeted therapy
17 MARKETED DRUGS
23 PIPELINE DRUGS
27 RECENT EVENTS AND ANALYST OPINION
27 Selumetinib for Thyroid Cancer (July 26, 2018)
28 Lenvima for Thyroid Cancer (July 3, 2018)
29 LOXO-292 for Thyroid Cancer (June 2, 2018)
31 Cabometyx / Cometriq for Thyroid Cancer (February 13, 2018)
33 Iclusig for Thyroid Cancer (January 9, 2017)
35 KEY UPCOMING EVENTS
36 KEY REGULATORY EVENTS
36 Bayer Files Larotrectinib In EU As LOXO-292 Hurtles Towards The Market
37 PROBABILITY OF SUCCESS
38 LICENSING AND ASSET ACQUISITION DEALS
38 NanoCarrier Gets Japanese Rights To VBL Cancer Gene Therapy
38 Takeda Adds Exelixis Arrow To Oncology Quiver
40 PARENT PATENTS
41 REVENUE OPPORTUNITY
42 CLINICAL TRIAL LANDSCAPE
43 Sponsors by status
44 Sponsors by phase
46 Prescription information
LIST OF FIGURES
14 Figure 1: Trends in incident cases of thyroid cancer, 2017–26
23 Figure 2: Pipeline drugs for thyroid cancer in the US
23 Figure 3: Pipeline drugs for thyroid cancer, by company
24 Figure 4: Pipeline drugs for thyroid cancer, by drug type
24 Figure 5: Pipeline drugs for thyroid cancer, by classifications
28 Figure 6: Selumetinib for Thyroid Cancer (July 26, 2018): Phase III – ASTRA
31 Figure 7: LOXO-292 for Thyroid Cancer (June 2, 2018): Phase I/II – LIBRETTO-001
33 Figure 8: Cabometyx / Cometriq for Thyroid Cancer (February 13, 2018): Phase II – RAI-DTC (Abramson)
35 Figure 9: Key upcoming events in thyroid cancer
37 Figure 10: Probability of success in the thyroid cancer pipeline
38 Figure 11: Licensing and asset acquisition deals in thyroid cancer
40 Figure 12: Parent patents in thyroid cancer
42 Figure 13: Clinical trials in thyroid cancer
42 Figure 14: Top 10 drugs for clinical trials in thyroid cancer
43 Figure 15: Top 10 companies for clinical trials in thyroid cancer
43 Figure 16: Trial locations in thyroid cancer
44 Figure 17: Thyroid cancer trials status
45 Figure 18: Thyroid cancer sponsors, by phase
LIST OF TABLES
13 Table 1: Incident cases of thyroid cancer, 2017–26
15 Table 2: Five-year prevalent cases of thyroid cancer, 2017–26
18 Table 3: Marketed drugs for thyroid cancer
21 Table 4: Approvals by country for thyroid cancer
25 Table 5: Pipeline drugs for thyroid cancer in the US
27 Table 6: Selumetinib for Thyroid Cancer (July 26, 2018)
28 Table 7: Lenvima for Thyroid Cancer (July 3, 2018)
29 Table 8: LOXO-292 for Thyroid Cancer (June 2, 2018)
32 Table 9: Cabometyx / Cometriq for Thyroid Cancer (February 13, 2018)
34 Table 10: Iclusig for Thyroid Cancer (January 9, 2017)
41 Table 11: Historical global sales, by drug ($m), 2013–17
41 Table 12: Forecasted global sales, by drug ($m), 2018–22
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email firstname.lastname@example.org for further help or assistance.